{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:27:08Z","timestamp":1776212828087,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006280","name":"Urology Care Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1NU58DP007156"],"award-info":[{"award-number":["1NU58DP007156"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.urology.2025.07.039","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:57:01Z","timestamp":1753286221000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Treatment Patterns for Non-muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Shortage"],"prefix":"10.1016","volume":"205","author":[{"given":"Daisy","family":"Obiora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Sharbaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jathin","family":"Bandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnathan G.","family":"Yabes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce L.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.07.039_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette-Guerin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib2","unstructured":"APhase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Na\u00efve High-Grade Non-Muscle Invasive Bladder Cancer Dana-Farber Cancer Institute"},{"key":"10.1016\/j.urology.2025.07.039_bib3","unstructured":"Group, E.-A. C. R.: A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Na\u00efve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE): clinicaltrials.gov, 2023."},{"key":"10.1016\/j.urology.2025.07.039_bib4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of Bacillus Calmette-Guerin-naive nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib6","doi-asserted-by":"crossref","unstructured":"Jacob JM, Guerrero-Ramos F, Necchi A, et al. TAR-200 monotherapy in patients with bacillus calmette-gu\u00e9rin\u2013unresponsive high-risk non\u2013muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from sunrise-1. Journal of Urology, 213.","DOI":"10.1097\/01.JU.0001111604.90306.91.03"},{"key":"10.1016\/j.urology.2025.07.039_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2016.06.014","article-title":"Association between number of endoscopic resections and utilization of Bacillus Calmette-Guerin therapy for patients with high-grade, non-muscle-invasive bladder cancer","volume":"15","author":"Lenis","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urology.2025.07.039_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer","volume":"143","author":"Martinez-Pineiro","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906)","volume":"173","author":"de Reijke","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib11","unstructured":"BCG Shortage Info - American Urological Association"},{"key":"10.1016\/j.urology.2025.07.039_bib12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.purol.2020.12.012","article-title":"BCG strain shortage from 2012 to 2014: evaluation of its impact on the management of patients with high-risk NMIBC","volume":"31","author":"Surlemont","year":"2021","journal-title":"Prog Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: rationalizing the shortage of Bacillus Calmette-Guerin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2025.07.039_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Guerin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urology.2025.07.039_bib16","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.urology.2025.07.039_bib17","unstructured":"BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment: U.S. Food and Drug Administration, August 2024."},{"key":"10.1016\/j.urology.2025.07.039_bib18","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with Bacillus Calmette-Guerin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.039_bib19","unstructured":"Inspections, Compliance, Enforcement, and Criminal Investigations: U.S. Food and Drug Administration, 7\/12\/2012."},{"key":"10.1016\/j.urology.2025.07.039_bib20","unstructured":"An Update on the Supply and Production of Bacille Calmette-Gu\u00e9rin: ASCO Daily News"},{"key":"10.1016\/j.urology.2025.07.039_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.urology.2020.08.004","article-title":"Contemporary treatment patterns for non-muscle-invasive bladder cancer: has the use of radical cystectomy changed in the BCG shortage era?","volume":"147","author":"Tully","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.07.039_bib22","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.3390\/cancers15143746","article-title":"Diminished short-term efficacy of reduced-dose induction BCG in the treatment of non-muscle invasive bladder cancer","volume":"15","author":"Ostrowski","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.urology.2025.07.039_bib23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs - the case of intravesical BCG for bladder cancer","volume":"376","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.07.039_bib24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bju.15661","article-title":"Reduced-dose bacillus Calmette-Guerin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre","volume":"130","author":"Lobo","year":"2022","journal-title":"BJU Int"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525007113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525007113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:08:00Z","timestamp":1772802480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525007113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"alternative-id":["S0090429525007113"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.07.039","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns for Non-muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Shortage","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.07.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}